RecruitingNot ApplicableNCT06567665

Leucine Supplementation Strategies to Enhance Muscle Anabolic Responses in Older Age


Sponsor

University of Nottingham

Enrollment

10 participants

Start Date

Aug 5, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

Sarcopenia describes the progressive decline of muscle mass and strength with advancing age and is associated with increased frailty and morbidity, however we do not currently have an effective treatment. Protein feeding and exercise is known to increase muscle mass, but aged muscle shows a lower response to these stimuli leading to muscle loss over time. We do know that ingesting leucine, a building block of protein, can overcome this reduced response to protein feeding and exercise leading to increased muscle mass in older people. However, we do not understand when the optimum time to ingest leucine is to maximise muscle mass after exercise in older people. In this study we will examine the effect of feeding leucine after exercise either with a meal or between meals.


Eligibility

Sex: MALEMin Age: 65 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Leucine for people with muscle protein synthesis. The study is currently recruiting participants at 1 location. People eligible for this study include men aged 65 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIETARY_SUPPLEMENTLeucine

Leucine is a dietary supplement that can be easily purchased over the counter at health food stores. It is an essential amino acid and is involved in stimulate muscle protein synthesis.


Locations(1)

University of Nottingham

Nottingham, Nottinghamshire, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06567665


Related Trials